A pilot monocentric analysis of efficacy and safety of Fludarabine-Campath combination (Flucam) as first line treatment in elderly patients with chronic lymphocytic leukaemia and Tp53 disfunction.

摘要

Chronic lymphocytic leukaemia (CLL) is a leukaemia of the elderly. Patients with CLL and TP53 disruption, by 17p13 deletion (17pdel) and/or mutation (TP53~- CLL) represent the group with the poorest outcome (Dohner et al, 2000; Forconi et al, 2008; Zenz et al, 2008; Rossi et al, 2009). The emergence of additional molecular aberrations, particularly after treatment, may cause further differential outcome (Forconi et al, 2008). Thus, an effective strategy upfront is still required for TP53" CLL.